NDAORALTABLET
Approved
Jun 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
MEKTOVI (binimetinib) by Pfizer is mitogen-activated extracellular signal regulated kinase 1 (mek1) and mek2 activity. Approved for melanoma. First approved in 2018.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEKTOVI (binimetinib) is an oral MEK1/MEK2 inhibitor approved by the FDA in June 2018 for the treatment of lung cancer, specifically non-small cell lung cancer (NSCLC) with BRAF V600E mutations. The drug works by inhibiting extracellular signal-regulated kinase (ERK) phosphorylation in the RAS/RAF/MEK/ERK pathway, blocking tumor cell proliferation. It is primarily used in combination with encorafenib (BRAFTOVI), another Pfizer oncology product targeting BRAF, to achieve synergistic anti-tumor activity and delay resistance emergence compared to monotherapy.
$0.1BPart D
7.5 years to LOEMechanism of Action
mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activity. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway. In vitro, binimetinib inhibited extracellular signal-related kinase (ERK) phosphorylation in cell-free assays as well as…
Indications (1)
Worked on MEKTOVI at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.